STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Boudadi, Karim
Suzman, Daniel L.
Luber, Brandon
Wang, Hao
Silberstein, John L.
Taylor, Maritza N.
Sullivan, Rana
Dowling, Donna
Harb, Rana
Dittamore, Ryan Vance
Meeker, Alan
Luo, Jun
Drake, Charles G.
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[4] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Epic Sci, San Diego, CA USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5089
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase-III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - Study AP 118/21 of the AUO
    Rexer, H.
    Boegemann, M.
    Hammerer, P.
    UROLOGE, 2022, 61 (03): : 345 - 346
  • [42] AR-V7-a novel predictive and prognostic Biomarker Therapy Individualization in castration-resistant Prostate Cancer
    Oing, C.
    von Amsberg, G.
    Bokemeyer, C.
    ONKOLOGE, 2015, 21 (09): : 846 - 847
  • [43] Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, S. F.
    Beer, T. M.
    Higano, C. S.
    Tejwani, S.
    Hamid, O.
    Picus, J.
    Harzstark, A.
    Scher, H. I.
    Lan, Z.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Mohebtash, M.
    Madan, R. A.
    Arlen, P. M.
    Rauckhorst, M.
    Tsang, K. Y.
    Cereda, V.
    Vergati, M.
    Poole, D. J.
    Dahut, W. L.
    Schlom, J.
    Gulley, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).
    Scher, Howard I.
    Graf, Ryon P.
    Schreiber, Nicole A.
    Winquist, Eric
    McLaughlin, Brigit
    Lu, David
    Orr, Sarah
    Fleisher, Martin
    Lowes, Lori
    Anderson, Amanda K. L.
    Wang, Yipeng
    Dittamore, Ryan Vance
    Allan, Alison L.
    Attard, Gerhardt
    Heller, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gulley, James L.
    Madan, Ravi A.
    Tsang, Kwong Y.
    Jochems, Caroline
    Dahut, William L.
    Schlom, Jeffrey
    CANCER RESEARCH, 2013, 73
  • [47] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
    Luo, Jun
    ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (04) : 580 - 585
  • [49] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345